Severity
Moderate
FDA Drug recall · Reported July 29, 2026
Lack of Assurance of Sterility
Rohto-Mentholatum (Vietnam) Co., Ltd. recalled Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2… - a moderate-severity action.
Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2… was recalled by Rohto-Mentholatum (Vietnam) Co., Ltd. in July 29, 2026. Reason: Lack of Assurance of Sterility. Check the official notice for the remedy. Verify recall #D-0722-2026 with the FDA Drug before acting.
The recall
Rohto-Mentholatum (Vietnam) Co., Ltd. issued this moderate-severity FDA Drug recall-Lack of Assurance of Sterility.
Sourced from official FDA Drug enforcement records. Verify recall #D-0722-2026 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0722-2026) was formally reported on July 29, 2026, with the manufacturer initiating the action on July 14, 2026. It is classified under Moderate severity (Class II), with a current status of Ongoing. Rohto-Mentholatum (Vietnam) Co., Ltd. is listed as the recalling firm, operating out of Ho Chi Minh, N/A. Federal records list the affected scope as 2910148 cartons.
The documented reason for this recall is: Lack of Assurance of Sterility Distribution data in the federal record shows the product reached: Nationwide within the United States. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls, 6 from FDA Drug and 1 from Rohto-Mentholatum (Vietnam) Co., Ltd. - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 14,436 drugs & medications recalls on record
Of 88,001 recalls with an agency hazard classification, 19,020 are high severity, 64,468 moderate, and 4,513 low. A further 16,157 CPSC/NHTSA recalls have no agency class and are excluded from this split. This recall is classified moderate severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Moderate
Affected scope
2910148 cartons
Related Recalls
6
6 from same agency
Rohto Cooling Eye Drops Cool Relief (naphazoline hydrochloride 0.012%, polysorbate 80 0.2%), Sterile, 0.4 FL OZ (13 mL) each, Distributed by: The Mentholatum Company, Orchard Park, NY 14127, Made in Vietnam, UPC 310742010749, NDC 10742-8141-1
Lack of Assurance of Sterility
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Moderate (Class II) |
| Status | Ongoing |
| Recall number | D-0722-2026 |
| Date reported | July 29, 2026 |
| Date initiated | July 14, 2026 |
| Recalling firm | Rohto-Mentholatum (Vietnam) Co., Ltd. |
| Firm location | Ho Chi Minh, N/A |
| Affected scope | 2910148 cartons |
| Distribution | Nationwide within the United States |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Showing 5 of 14436 other recalls in this category.
Rohto-Mentholatum (Vietnam) Co., Ltd. · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Major Pharmaceuticals · 2026-07-29
Fresenius Kabi USA, LLC · 2026-07-29
Compare this recall with Rohto Cooling Eye Drops Max Strength (naphazoline hydrochlo… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported July 29, 2026. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of August 2026.